#USA #Plainsboro #Type 2 Diabetes #Ozempic® #Mounjaro®

New Real-World Study on Ozempic® and Mounjaro®

In a compelling new study presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, Novo Nordisk shared findings from a retrospective analysis focusing on adults with type 2 diabetes. This study has brought to light important insights about the cardiovascular risks associated with two leading medications: Ozempic® (semaglutide) and Mounjaro® (tirzepatide).

Study Overview

The research analyzed the health records of 636,525 adults diagnosed with type 2 diabetes who were on a semaglutide injection starting at 1 mg. When their dosage was escalated to 2 mg, it was associated with a 6% lower risk of experiencing major adverse cardiovascular events (MACE) compared to those who transitioned to Mounjaro® at doses up to 15 mg. The analysis specifically considered risks such as all-cause death, heart attacks, and strokes. Notably, the results revealed that 67.2% of the initial participants stayed on semaglutide at 1 mg, while 29.2% chose to increase their dosage to 2 mg and 3.6% decided to switch to Mounjaro® within the first year of the study.

Insights on Treatment Adjustments

As outlined by Dr. Michael Radin, the executive medical director at Novo, it's crucial for healthcare professionals to consider cardiovascular risks while determining treatment plans for their patients. The findings stress the importance of dosage adjustments in existing therapies rather than solely opting for a transition to alternative treatments. This is vital for maintaining effective glycemic control while minimizing cardiovascular risks, a standard concern for anyone managing diabetes.

Furthermore, the study findings may aid in shaping future therapy decisions. According to Kathryn S. Tierney, a representative from Middlesex Health, the data suggest that elevating the dosage of semaglutide may provide a safer path forward than switching entirely to another medication, particularly for individuals who are already coping well with their current treatment.

Long-Term Observations and Limitations

The study conducted follow-ups over 720 days, revealing an ongoing trend in treatment intensification as the cohort evolved. However, while establishing correlations between treatment intensification and cardiovascular outcomes, it's important to acknowledge that real-world studies may have inherent limitations, including possible confounding factors not accounted for and the lack of randomized control like that seen in clinical settings.

Conclusion

Novo Nordisk's findings affirm the significance of continued research and real-world evidence in understanding treatment impacts for diabetes. The implications of these results may help guide healthcare practitioners to better form treatment plans that prioritize patient safety and health outcomes, especially in relation to cardiovascular health concerns tied to diabetes management. As with all medications, patients and doctors should discuss the potential risks and safety profiles, including the known warnings associated with semaglutide injections.

As Novo Nordisk continues to pioneer advancements in diabetic care, the overarching goal remains clear: enhancing the quality of life for all individuals affected by diabetes, ensuring every treatment decision is backed by robust evidence and support.